Bristol-myers Squibb Compnay

Jeffrey Jackson

Nils Lonberg

John P Cogswell

Raphael Clynes

Robin Edwards

James Novotny, Jr

Cyrus Hedvat

Christopher Harbison

Darren Locke

Zachary Ingwer

Justin Boyle

Jacob Jolly

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to Fucosyl-GM1.

Treatment of lung cancer using an anti-fucosyl-GM1 antibody

The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.

Treatment of LAG-3 positive tumors

Growing community of inventors

Schwenksville, PA, United States of America

Jeffrey Jackson